AzTrials
AzTrials

Hodgkin LymphomaPhase 3RADARNCT04685616

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

A Phase 3 study testing Involved site radiotherapy, Doxorubicin and Bleomycin in people with Hodgkin Lymphoma, run by University College, London at 72 sites in 12 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Read more about this study

Who is it for?
Ages 16 to 69 years
Conditions the study is for
Hodgkin Lymphoma
What is being tested?
Involved site radiotherapy, Doxorubicin and Bleomycin
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,042 participants
Where
72 sitesin 12 countries
Study dates
14 Apr 2022to Sep 2032
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 to 69 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Males and females aged 16-69 years (inclusive) (age range is 18-69 in US and EU)
  • Histologically confirmed classical Hodgkin lymphoma
  • Stage I or II supradiaphragmatic disease with no mediastinal bulk disease (defined as greater than a third of the transthoracic diameter at any level of thoracic vertebra as determined by CT) or B symptoms. Bulky disease at other sites is acceptable. Extranodal disease (single extranodal site (stage I) or contiguous nodal extension (stage II)) is acceptable.
  • ECOG performance status 0-2.
  • No previous treatment for Hodgkin lymphoma
  • Fit to receive anthracycline-based chemotherapy (patients with a history of ischaemic heart disease or hypertension should have a left ventricular ejection fraction of ≥50%)
Show all 13Show fewer
  • Creatinine clearance (measured or calculated >40ml/min
  • Total bilirubin <1.5 x upper limit of normal, unless attributable to disease or known Gilbert's syndrome
  • ALT or AST < 2 x upper limit of normal
  • Adequate bone marrow function with neutrophils ≥1.0x10^9/l and platelets ≥100x10^9/l
  • Haemoglobin ≥8g/dL
  • Willing and able to comply with the requirements of the protocol, including contraceptive advice, where applicable
  • Written informed consent

Who cannot join

  • Previous treatment for Hodgkin lymphoma, excluding short courses of oral corticosteroids at a dose of 100mg prednisolone (or equivalent) for up to 7 days
  • Infradiaphragmatic disease
  • Nodular lymphocyte predominant Hodgkin lymphoma
  • Absence of FDG-avid lesions on baseline PET scan
  • Age 70 years or over or age 15 years or under
  • Other cancer diagnosed with the last 5 years. Patients with completely excised carcinoma in situ of any type and basal or squamous cell carcinoma of the skin are not excluded
Show all 17Show fewer
  • Recurrent or persistent other cancer within last 5 years irrespective of date of initial diagnosis
  • Pre-existing grade ≥1 sensory or motor neuropathy from any cause
  • History of or current progressive multi-focal leukoencephalopathy or other chronic condition of the brain
  • Symptomatic neurologic disease compromising normal activities of daily living or requiring medications
  • Infection with HIV, hepatitis C or active hepatitis B infection (surface antigen or DNA positive)
  • Any active systemic viral, bacterial or fungal infection requiring systemic antibiotics, antivirals or antifungals within 2 weeks prior to first trial drug dose
  • Receiving or recently treated with any other investigational agent (within 4 weeks of trial entry)
  • Pregnant or breastfeeding women
  • Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin or any component of ABVD
  • Known history of any cardiovascular or respiratory conditions that would preclude anthracycline or bleomycin administration
  • Other significant medical or psychiatric comorbidity that in the opinion of the investigator would make administration of ABVD or A2VD hazardous

Trial locations and contacts

72 sites in 12 countries. Contact the study team or a site near you to ask about taking part.

RADAR Trial Coordinator contact

+44(0)207 679 9860

ctc.radar@ucl.ac.uk

72 sites in 12 countries

United Kingdom31 sites, 31 recruiting

  • Aberdeen Royal Infirmary

    Aberdeen, AB25 2ZN

    Dominic Culligan

    Dominic Culligan

    Recruiting

  • Hampshire Hospitals NHS Foundation Trust

    Basingstoke, Hampshire, RG24 9NA

    Katie Smith, katherine.smith1@hhft.nhs.uk

    Katie Smith

    Recruiting

  • University Hospitals Birmingham

    Birmingham, B15 2GW

    Lindsay George, lindsay.george3@uhb.nhs.uk

    Lindsay George

    Recruiting

  • Blackpool Victoria Hospital

    Blackpool, Lancashire, FY3 8NR

    Mac Macheta

    Mac Macheta

    Recruiting

  • Glan Clwyd Hospital

    Bodelwyddan, LL18 5UJ

    Earnest Heartin, earnest.heartin@wales.nhs.uk

    Earnest Heartin

    Recruiting

  • Bristol Haematology and Oncology Centre

    Bristol

    Claire Burney

    Claire Burney

    Recruiting

  • University Hospital of Wales, Cardiff & Vale University Local Health Board

    Cardiff, CF14 4XW

    Eve Gallop-Evans

    Eve Gallop-Evans

    Recruiting

  • Colchester Hospital, ESNEFT

    Colchester, CO4 5JL

    Gavin Campbell, gavin.campbell@esneft.nhs.uk

    Gavin Campbell

    Recruiting

  • University Hospital Coventry

    Coventry, CV2 2DX

    Duncan Murray, duncan.murray@uhcw.nhs.uk

    Duncan Murray

    Recruiting

  • Lanarkshire

    Glasgow, Scotland, G71 8BB

    Charlotte Thomas

    Charlotte Thomas

    Recruiting

  • Beatson West of Scotland Cancer Centre

    Glasgow, G12 0YN

    Pam McKay

    Pam McKay

    Recruiting

  • Castle Hill Hospital

    Hull, HU16 5JQ

    Russell Patmore

    Russell Patmore

    Recruiting

  • St James University Hospital

    Leeds, LS9 7TF

    Catherine Burton, cathy.burton1@nhs.net

    Catherine Burton

    Recruiting

  • University Hospitals of Leicester NHS Trust

    Leicester, LE1 5WW

    Sapna Ladani

    Sapna Ladani

    Recruiting

  • The Clatterbridge Cancer Centre NHSFT, 65 Pembroke Place

    Liverpool, L7 8YA

    Nagesh Kalakonda

    Nagesh Kalakonda

    Recruiting

  • St George's Hospital

    London, Tooting, SW17 0QT

    Ruth Pettengell

    ruth.pettengell2@stgeorges.nhs.uk

    Recruiting

  • St Bartholomew's Hospital

    London, EC1A 7BE

    Rebecca Auer

    Rebecca Auer

    Recruiting

  • University College London Hospitals NHS Foundation Trust (UCLH)

    London, NW1 2BU

    Maria Marzolini

    Maria Marzolini

    Recruiting

  • Royal Marsden Hospital Chelsea

    London, SW3 6JZ

    Sunil Iyengar, Sunil.Iyengar@rmh.nhs.uk

    Sunil Iyengar

    Recruiting

  • Christie Hospital

    Manchester, M20 4BX

    Beth Phillips, beth.phillips@manchester.ac.uk

    Timothy Illidge, tim.illidge@manchester.ac.uk

    Recruiting

  • Freeman Hospital, Newcastle

    Newcastle upon Tyne, Newcastle, NE7 7DN

    Wendy Osborne

    Wendy Osborne

    Recruiting

  • Norfolk & Norwich University Hospital

    Norwich, NR4 7UY

    Nimish Shah

    Nimish Shah

    Recruiting

  • Nottingham University Hospitals NHST

    Nottingham, NG51PB

    Emily Chernucha

    Emily Chernucha

    Recruiting

  • Churchill Hospital

    Oxford, OX3 7LE

    Graham Collins

    Graham Collins

    Recruiting

  • Derriford Hospital

    Plymouth, PL6 8DH

    Patrick Medd

    Patrick Medd

    Recruiting

  • Royal Hallamshire Hospital

    Sheffield, S10 2JF

    Nick Morley, nick.morley@nhs.net

    Nick Morley

    Recruiting

  • Southampton General Hospital

    Southampton, SO16 6YD

    Andrew Davies, andrew.davies@uhs.nhs.uk

    Andrew Davies

    Recruiting

  • Sunderland Royal Hospital

    Sunderland, SR4 7TP

    Scott Marshall, scott.marshall3@nhs.net

    Scott Marshall

    Recruiting

  • Royal Marsden Hospital

    Sutton, SM2 5PT

    Sunil Iyengar, Sunil.Iyengar@rmh.nhs.uk

    Sunil Iyengar

    Recruiting

  • Torbay Hospital

    Torquay, TQ2 7AA

    Deborah Turner

    Deborah Turner

    Recruiting

  • Royal Cornwall Hospital

    Truro, TR1 3LJ

    Bryson Pottinger

    Bryson Pottinger

    Recruiting

Other trials in United Kingdom

Australia10 sites, 10 recruiting

  • Royal Adelaide Hospital

    Adelaide, 5000

    Pratyush Giri

    Pratyush Giri

    Recruiting

  • Box Hill Hospital

    Box Hill, VIC 3128

    Denise Lee

    Denise Lee

    Recruiting

  • Royal Brisbane and Women's Hospital

    Brisbane, QLD 4006

    Nicholas Weber

    Nicholas Weber

    Recruiting

  • Royal Darwin Hospital

    Darwin, NT 0810

    Emma Palfreyman

    Emma Palfreyman

    Recruiting

  • Liverpool Hospital

    Liverpool

    Vu M Hua, 02 8738 5167, Minh.Hua@health.nsw.gov.au

    Vu M Hua

    Recruiting

  • Sunshine Hospital (Western Health)

    Melbourne, VIC 3021

    Michael Gilbertson

    Michael Gilbertson

    Recruiting

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, 2065

    Keith Fay

    Keith Fay

    Recruiting

  • Concord Repatriation General Hospital

    Sydney, NSW 2139

    Nicole Wong Doo

    Nicole Wong Doo

    Recruiting

  • St George Hospital

    Sydney, NSW 2217

    Fernando Roncolato

    Fernando Roncolato

    Recruiting

  • Townsville University Hospital

    Townsville, Queensland, QLD 4814

    Jane Royle, Jane.Royle@health.qld.gov.au

    Jane Royle

    Recruiting

Other trials in Australia

Canada7 sites, 7 recruiting

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, B3H 3A7

    Becky Veinot

    Nicholas Forward

    Recruiting

  • Juravinski Cancer Centre

    Hamilton, Ontario, L8V 5C2

    Edna Wilson

    Joanne Britto

    Recruiting

  • Ottowa Hospital Research Institute

    Ottawa, K1Y 4E9

    Ashley-Ann Emond

    Isabelle Bence-Bruckler

    Recruiting

  • Saint John Regional Hospital

    Saint John, E2L 4L2

    Sharon Turnell

    Alfonso Riviera Duarte

    Recruiting

  • University Health Network Princess Margaret Cancer Centre

    Toronto, M5G 2M9

    Marie Kirchmeyer

    Michael Crump

    Recruiting

  • Vancouver Cancer Centre

    Vancouver, V5Z 4E6

    Niamh McMahon

    Kerry Savage

    Recruiting

  • CancerCare Manitoba

    Winnipeg, R3E 0V9

    Tianna Rarama

    Leonard Minuk

    Recruiting

Other trials in Canada

Belgium5 sites, 5 recruiting

  • Universitair Ziekenhuis Antwerpen

    Antwerp

    Eva De Backer Dr, Eva.debacker2@uza.be

    Eva De Backer

    Recruiting

  • Ziekenhuis Netwerk Antwerpen

    Antwerp

    Ka Lung Wu, kalung.wu@zna.be

    Ka Lung Wu

    Recruiting

  • UZ Leuven

    Leuven

    Sherida Woei-A-Jin, sherida.woei-a-jin@uzleuven.be

    Sherida Woei-A-Jin

    Recruiting

  • CHU-UCL Namur

    Namur

    Vincent Remouchamps, vincent.remouchamps@uclouvain.be

    Vincent Remouchamps

    Recruiting

  • AZ Delta Campus Rumbeke

    Roeselare, West Flanders, Deltalaan 1, 8800

    Caressa Meert, caressa.meert@azdelta.be

    Caressa Meert

    Recruiting

Other trials in Belgium

Netherlands5 sites, 5 recruiting

  • Amsterdam UMC - location VUMC

    Amsterdam, 1081 HV

    Sanne Tonnio

    Sanne Tonnio

    Recruiting

  • Reinier de Graafweg 3-11 - Postbus 5011 - 2625 AD Delft

    Delft

    Posthuma Ward

    Posthuma Ward

    Recruiting

  • Universitair Medisch Centrum Groningen

    Groningen

    Wouter Plattel, w.j.plattel@umcg.nl

    Wouter Plattel

    Recruiting

  • Radboud University Medical Center Nijmegen

    Nijmegen

    Wendy Stevens, Wendy.Stevens@radboudumc.nl

    Recruiting

  • NL 331 - Haaglanden Medisch Centrum (HMC) - Haaglanden MC

    The Hague

    Liane te Boome, l.te.boome@haaglandenmc.nl

    Liane Te Boome

    Recruiting

Other trials in Netherlands

United States3 sites, 3 recruiting

  • University of Miami School of Medicine

    Miami, Florida, 33136

    Safia Sawleh

    Craig Moskowitz

    Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065

    Pamela Park

    Alison Moskowitz

    Recruiting

  • Stanford University - (Stanford Cancer Institute)

    Stanford, California, 94305

    Austin Yeung

    Ranjana Advani

    Recruiting

Other trials in United States

Ireland3 sites, 3 recruiting

  • St James's Hospital

    Dublin

    Robert Henderson, rhenderson@stjames.ie

    Robert Henderson

    Recruiting

  • St. Vincent's University Hospital

    Dublin

    Liam Smyth, liamsmyth@svhg.ie

    Liam Smyth

    Recruiting

  • University Hospital Galway

    Galway

    Amjad Hayat, Amjad.hayat@hse.ie

    Amjad Hayat

    Recruiting

Other trials in Ireland

Spain3 sites, 3 recruiting

  • Hospital Del Mar

    Barcelona, ES 08003

    Blanca Sanchez Gonzalez, 97894@parcdesalutmar.cat

    Blanca Sanchez Gonzalez

    Recruiting

  • Institut Catala d'Oncologia

    Barcelona, ES 08908

    Sureda-Balari Anna

    Sureda-Balari Anna

    Recruiting

  • Complejo Hospitalario de Navarra

    Pamplona

    Jose Arguinano, jm.arguinano.perez@navarra.es

    Jose Arguinano

    Recruiting

Other trials in Spain

Denmark2 sites, 2 recruiting

  • Aarhus University Hospitak Skjeby

    Aarhus

    Peter Kamper, petekamp@rm.dk

    Peter Kamper

    Recruiting

  • Rigshospitalet

    Copenhagen

    Martin Hutchings, martin.hutchings@regionh.dk

    Martin Hutchings

    Recruiting

Other trials in Denmark

New Zealand1 site, 1 recruiting

  • Auckland City Hospital

    Auckland, 1023

    Leanne Berkahn

    Leanne Berkahn

    Recruiting

Other trials in New Zealand

Portugal1 site, 1 recruiting

  • Instituto Portugues de Oncologia de Lisboa Francisco Gentil

    Lisbon

    Susana Carvalho, susanacoelhocarvalho@hotmail.com

    Susana Carvalho

    Recruiting

Other trials in Portugal

Slovakia1 site, 1 recruiting

  • Narodny Onkologicky Ustav

    Bratislava

    Andrej Vranovsky, andrej.vranovsky@nou.sk

    Andrej Vranovsky

    Recruiting

Other trials in Slovakia

About this study

Official title: A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma

RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will be combined to achieve the total sample size. Data analysis will be performed by UCL and therefore UCL is responsible for the clinicaltrials.gov entry.

Eligible patients will be randomised to receive either ABVD or A2VD chemotherapy.

Read more

An interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as consolidation.

Patients will be followed up for a minimum of 5 years after treatment.

Read the detailed description

Eligible patients will be randomised to receive either ABVD chemotherapy (doxorubicin, bleomycin, vinblastine and dacarbazine) or A2VD chemotherapy (doxorubicin, brentuximab vedotin, vinblastine and dacarbazine, with growth factor support).

If patients agree, they will have a PET-CT scan after 1 cycle (PET1). The result of this scan will be blinded and used for exploratory endpoints only. Treatment will not be influenced by the result of this scan.

All patients will have a PET-CT scan after 2 cycles of treatment (PET2) which will be centrally reviewed. The Deauville score from central review will be used to risk adapt subsequent therapy as follows:

  • Patients with Deauville score 1-3 will have one further cycle of their randomised chemotherapy and then enter follow up.
  • Patients with Deauville score 4 will have two further cycles of their randomised chemotherapy followed by involved site radiotherapy
  • Patients with Deauville score 5 will be withdrawn from trial treatment. They will have further treatment at their treating clinician's discretion and will enter follow up for the trial.

Patients with Deauville score 4 on PET2 will have a final PET-CT scan to confirm adequate treatment response.

Patients will be followed up for a minimum of 5 years after completing treatment.

Being tested
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine
Keywords
PET-response adapted, Stage IA/IIA Hodgkin lymphoma, Brentuximab vedotin
Medical subject headings
Hodgkin Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Involved site radiotherapyRadiation

    Involved site radiotherapy as per International Lymphoma Radiation Oncology Group (ILROG) guidelines.

    Recommended dose 30Gy

  • DoxorubicinDrug

    See arm description

  • BleomycinDrug

    See arm description

  • Brentuximab vedotinDrug

    See arm description

  • VinblastineDrug

    See arm description

  • DacarbazineDrug

    See arm description

  • Haematopoietic growth factorDrug

    Also called Filgrastim, G-CSF, Pegfilgrastim

    See arm description

Study groups in NCT04685616
Study groupRoleWhat they receive
ABVD +/- ISRTActive comparator2 x 28 day cycles of ABVD: Doxorubicin 25mg/m^2 IV days 1 \& 15 Bleomycin 10000 IU/m^2 days 1 \& 15 Vinblastine 6mg/m^2 days 1 \& 15 Dacarbazine 375mg/m^2 days 1 \& 15 PET-CT after 2 cycles will determine subsequent treatment: Deauville score 1-3 (PET CMR): 1 further cycle of ABVD then follow up Deauville score 4 (PET positive): 2 further cycles of ABVD followed by involved site radiotherapy (ISRT) Deauville score 5: withdraw from trial treatment; further treatment will be given at the treating clinician's discretion. Enter follow up for the trial.
Receives: Radiation: Involved site radiotherapy; Drug: Doxorubicin; Drug: Bleomycin; Drug: Vinblastine; Drug: Dacarbazine
A2VD +/- ISRTExperimental2 x 28 day cycles of A2VD: Doxorubicin 25mg/m^2 IV days 1 \& 15 Brentuximab vedotin 1.2mg/kg (max 120mg) days 1 \& 15 Vinblastine 6mg/m^2 days 1 \& 15 Dacarbazine 375mg/m^2 days 1 \& 15 Filgrastim (or equivalent haematopoietic growth factor) for 5-7 days from day 2 and day 16 (or single dose of peg-filgrastim on days 2 \& 16) PET-CT after 2 cycles will determine subsequent treatment: Deauville score 1-3 (PET CMR): 1 further cycle of A2VD then follow up Deauville score 4 (PET positive): 2 further cycles of A2VD followed by involved site radiotherapy (ISRT) Deauville score 5: withdraw from trial treatment; further treatment will be given at the treating clinician's discretion. Enter follow up for the trial.
Receives: Radiation: Involved site radiotherapy; Drug: Doxorubicin; Drug: Brentuximab vedotin; Drug: Vinblastine; Drug: Dacarbazine; Drug: Haematopoietic growth factor

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression free survival (PFS)

    Time from randomisation to first date of progression or death

    Measured: 3 years from end of treatment

Secondary outcomes (5)

  1. PET-CMR (complete metabolic response) rate

    Proportion of patients who have Deauville score 1-3 on PET-CT scan

    Measured: At the end of cycle 2 (each cycle is 28 days)

  2. Event-free survival (EFS)

    Time from randomisation to first date of progression, death or a positive PET2 scan (whichever occurs first)

    Measured: 5 years from end of treatment

  3. Overall survival (OS)

    Time from randomisation to death

    Measured: 5 years from end of treatment

  4. Incidence of second cancers and cardiovascular disease

    Proportion in each arm who develop a second cancer or cardiovascular disease

    Measured: 5 years from end of treatment

  5. Safety and toxicity of ABVD and A2VD as described by CTCAE v5.0

    Numbers of patients experiencing a grade 3+ adverse event of each type will be presented and compared between the arms. Only patients who start treatment will be included

    Measured: From start of treatment to 30 days post treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Dec 2020
  2. Study start14 Apr 2022
  3. Primary completionSep 2030 (estimated)
  4. Study completionSep 2032 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
1,042 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04685616
Sponsor's protocol ID
RADAR
Other IDs
2020-005160-65, IISR X25041, UCL/15/0105, CCTG HD.12, IRB number 20230081
Acronym
RADAR
Status last verified
Mar 2026
First submitted
27 Nov 2020
Last updated
8 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Kreuzberger N, Goldkuhle M, von Tresckow B, Kobe C, Sickinger MT, Monsef I, Skoetz N. Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma. Cochrane Database Syst Rev. 2025 Mar 26;3(3):CD010533. doi: 10.1002/14651858.CD010533.pub3.

    PubMed 40135712

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Involved site radiotherapy, Doxorubicin and Bleomycin in people with Hodgkin Lymphoma, run by University College, London at 72 sites in 12 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 8 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 72 sites in United Kingdom, Australia, Canada, Belgium, Netherlands and 7 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact RADAR Trial Coordinator (+44(0)207 679 9860, ctc.radar@ucl.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression free survival (PFS) (time frame: 3 years from end of treatment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04685616, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2026; AzTrials last refreshed its copy on 8 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in